Say 'Neva Sell Teva' No More
Article By:
Vivian Lewis
Read
Monday, November 4, 2013 3:00 PM EDT
With Teva facing a board and top management in disarray, layoffs, a worker's strike, government criticism and more, it's time to sell.
In this article: TEVA
The Q Ratio And Market Valuation: Monthly Update
Article By:
Doug Short
Read
Monday, November 4, 2013 1:38 PM EDT
Is the market overprices? A look at the Q ratio.
In this article: SPY
Too Many Quarterlies
Article By:
Vivian Lewis
Read
Friday, November 1, 2013 4:25 PM EDT
Updates on Teva, Barrick Gold, Bombardier, AmBev, Ecopetrol, Dr Reddy, Posco's, Paddy Power plc, Odontoprev, Maxichem, Israel Chemicals and Potash of Saskatchewan.
The Case For Shorting Myriad Genetics
Article By:
Ketan Desai
Read
Friday, October 4, 2013 11:00 AM EDT
Many articles have been written about Myriad Genetics (MYGN) – some bullish, some bearish. This is a bearish article, looking at the company from a different angle.
In this article: MYGN
The Company You Keep Speaks Volumes: Novabay And Trius
Article By:
John Eastman
Read
Thursday, October 3, 2013 4:18 PM EDT
The great potential of a drug or remedy that may make it a significant seller and revenue driver for years to come is one thing. But the partners and interested parties early on and along the way suggests a depth that a long term stakeholder should pay attention to.
New Use For Paxil Could Mean Potential Blockbuster For GlaxoSmithKline
Article By:
Vivian Lewis
Read
Wednesday, December 19, 2012 6:00 AM EDT
GlaxoSmithKline's well known drug for depression, Paxil, is found to be successful in treating diabetes. A new use for an old drug could mean massive profits for GSK.
In this article: GSK
